Bajaj Finserv Healthcare Fund

An open ended equity scheme following pharma, healthcare and allied theme

Data as on 28th February 2025

Portfolio Strategy

The Bajaj Finserv Healthcare Fund is an open ended actively managed equity scheme which aims to provide long-term capital appreciation by investing 80-100% of total assets in equity and equity related securities of companies classified under 'Healthcare Equipment & Supplies, Healthcare Services, Pharmaceuticals & Biotechnology' as per Industry classification issued by AMFI from time to time and any other industry/sector that forms part of the benchmark index.

The Scheme may also invest in companies involved in other healthcare, pharmaceutical and allied sectors. The scheme would invest in stocks across market capitalization, however, may take concentrated exposure to certain stocks/sectors/industry.

Indian Healthcare sector



Source: ResearchAndMarkets, RedSeer, Invest India, Frost & Sullivan, Deloitte, Statista, Modor Intelligence, KPMG India

Fund Features

Category:
Thematic Fund

Inception Date:
27th December 2024

Fund Manager:
Mr. Nimesh Chandan and Mr. Sorbh Gupta (Equity portion)
Mr. Siddharth Chaudhary (Debt portion)

Benchmark:
BSE Healthcare Total Return Index (TRI)

Minimum Investment Amount:
Rs. 500/- and in multiples of Re. 1/- thereafter

SIP Frequency:
Daily , Weekly, Fortnightly, Monthly, Quarterly

Total Expense Ratio:
Regular- 2.36%
Direct- 0.61%

*AUM (IN CR):
Month end AUM - INR 283.46
*The closing AUM as reported to SEBI & AMFI in the Monthly Cumulative Report (MCR)

Entry load: Nil

Exit load: Refer page 2

Why invest in Bajaj Finserv Healthcare Fund?

1 Low correlation of the sector with the broader market

3 Potential to create wealth over long-term by riding the healthcare boom



2 Investment in **MEGATRENDS** by identifying the potential growth stories

4 Targeting future profit pool companies

Asset Allocation

Equities	92.21%
Reverse Repo / TREPS & Net Current Assets	7.79%



Composition By Industry (%)



Pharmaceuticals & Biotechnology	69.46%
Healthcare Services	12.43%
Personal Products	2.39%
Diversified FMCG	2.20%
Food Products	1.76%
Agricultural Food & other Products	1.12%
Retailing	1.00%
Insurance	0.89%
Industrial Products	0.53%
Chemicals & Petrochemicals	0.44%

Market Cap Allocation

Large Cap	38.79%
Mid Cap	26.01%
Small Cap	27.41%
Debt, Cash & Others	7.79%

Equity Holding

Name (Top 10 Holdings)	(% to NAV)
Divi's Laboratories Limited	9.15%
Sun Pharmaceutical Industries Limited	8.42%
Cipla Limited	8.29%
Dr. Reddy's Laboratories Limited	8.27%
Apollo Hospitals Enterprise Limited	5.00%
Biocon Limited	3.77%
Piramal Pharma Limited	3.46%
Syngene International Limited	3.03%
Neuland Laboratories Limited	2.63%
Torrent Pharmaceuticals Limited	2.46%
Other Equities	**37.74%**
Total Equities	**92.21%**

Exit Load

- if units are redeemed / switched out within 3 months from the date of allotment: 1% of applicable NAV.
- if units are redeemed/switched out after 3 months from the date of allotment, no exit load is payable.

PRODUCT LABEL

This product is suitable for investors who are seeking*:

- wealth creation over long term
- to invest predominantly in equity and equity related instruments of pharma, healthcare and allied companies.

*Investors should consult their financial advisers if in doubt about whether the product is suitable for them

SCHEME

RISKOMETER



The risk of the scheme is very high

BENCHMARK

RISKOMETER



The risk of the benchmark i.e. BSE Healthcare Total Return Index (TRI) is very high